



ELSEVIER

Contents lists available at ScienceDirect

IJID Regions

journal homepage: www.elsevier.com/locate/ijregi

Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

David Palma^{a,b,c,*}, Miguel Alarcón^{a,b,d}, Patricia García de Olalla^{a,b,e}, Juan-Miguel Guerras^{a,f}, Carles Pericas^{b,g}, Jorge García^h, María Jesús Barberá^h, Oscar Ayerdiⁱ, Mar Vera Garcíaⁱ, Andrés Román-Urrestarazu^{c,j}, María José Belza^{a,f,#}, Cristina Rius^{a,b,e,k,#}

^a Consorcio de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain

^b Servei d'Epidemiologia, Agència de Salut Pública de Barcelona, Barcelona, Spain

^c International Health Department, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands

^d Department of Paediatrics, Obstetrics and Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

^e Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (IRB Sant Pau), Barcelona, Spain

^f Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain

^g Departament de Medicina, Universitat de Barcelona, Barcelona, España

^h Unidad de STI y HIV Drassanes, Hospital Vall d'Hebron, Barcelona, Spain

ⁱ Centro Sanitario Sandoval, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Madrid, Spain

^j Department of Psychiatry, University of Cambridge, Cambridge, UK

^k Department of Experimental and Health Sciences, Faculty of Health and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain

ARTICLE INFO

Keywords:

Hepatitis C

Sexually transmitted diseases

GBMSM

Men who have sex with men

Sexual health

Epidemiology

ABSTRACT

Objectives: Hepatitis C virus (HCV) has been recognized as a sexually transmitted infection (STI) in HIV-positive men who have sex with men (MSM), with an increased notification in HIV-negative MSM. The aim of this study was to determine the prevalence of HCV antibody and active HCV infection in HIV-negative gay, bisexual, and other MSM (GBMSM), and their characteristics, in Barcelona and Madrid, from March 2018 to March 2021.

Methods: Cross-sectional study conducted on 3548 HIV-undiagnosed GBMSM, across four HIV/STI testing centers. Respondents submitted an online, self-administered questionnaire after consultation, which collected information on sociodemographics, sexual health history, HCV knowledge, and substance consumption. Prevalence of HCV antibodies was determined by a reactive result in a rapid anti-HCV test or enzyme-linked immunosorbent assay (ELISA), while active HCV infection was determined by participants who were also positive on an HCV-RNA test. Crude and adjusted Poisson analyses with robust variance are presented for both prevalence and active infection.

Results: In total, 97.6% of participants (n = 3463) were HIV-negative. Of those, 18 were found to have HCV antibodies (0.52%), of which nine (0.26%) were also HCV-RNA positive. Those with HCV antibodies were associated to have lived with an HCV (+) person (adjusted prevalence ratio [APR]: 7.84, [95% confidence interval: 2.50-24.53]), using injectable drugs for sex (APR: 6.92, [1.20-39.79]) and testing positive for an STI in the previous year (APR: 4.06, [1.09-15.12]). Presenting an active infection was strongly associated with a previous HCV diagnosis (APR: 100.82 [22.16-458.76]), sexualized injectable drug use (APR: 17.53 [2.70-113.76]), and sharing douching material (APR: 7.45, [2.12-25.95]).

Conclusion: Sexual practices with a higher risk of bleeding and sexualized drug use, particularly sexualized injectable drug use, were associated with higher rates of HCV diagnosis in GBMSM. Identifying these practices during consultation, contact tracing new cases and regularly testing those with a previous history of HCV, will facilitate HCV eradication.

* Corresponding author.

E-mail address: ext_dpalma@aspb.cat (D. Palma).

María José Belza and Cristina Rius have contributed equally to this work and share senior authorship.

<https://doi.org/10.1016/j.ijregi.2023.07.001>

Received 5 May 2023; Received in revised form 4 July 2023; Accepted 4 July 2023

2772-7076/© 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Introduction

Untreated hepatitis C virus (HCV) is a leading cause of hepatitis C-related liver disease, cirrhosis, and hepatocellular carcinoma [1,2]. With an estimated 71 million chronically infected patients worldwide, HCV epidemics affect all World Health Organization (WHO) regions, although prevalence is higher in region European and the Eastern Mediterranean [2], partly due to testing practices [3]. In 2019, there were an estimated 1.5 million new cases of HCV and an additional 290,000 deaths related to HCV infection [4].

In recent years, the implementation of direct-acting antivirals (DAA) has transformed the prognosis of the infection into a completely curable disease, favorably reducing HCV mortality [4–6]. In 2016, the WHO adopted the first global health sector strategy on viral hepatitis, setting targets for HCV eradication by 2030 [7]. As one of the few countries on track to reach the WHO goals by 2030 [2,6], Spain developed its 2015 Strategic Plan for the Approach to Hepatitis [8], which includes the widespread use of DAAs.

Since early 2000, HCV has been considered a sexually transmitted infection (STI), particularly in gay, bisexual, and other men who have sex with men (GBMSM) [2,5,7,9,10]. Within this key population, those with an HIV diagnosis have an increased risk of HCV acquisition [7,9,11]. Some proposed explanation includes serosorting practices during the widespread initiation of combined antiretroviral therapy in the US and Western Europe ever since the 1990s, which may lead to condomless anal sex [9]. Furthermore, the rise of sexualized drug use or chemsex [11], especially the increase in sexualized injection drug use (slam-sex or slamming) [9,12,13] has been associated with an increase in HCV cases. Additional blood-sharing risk practices include having multiple sexual partners, sharing douching materials, and/or sexual practices which may damage anal mucosa (fisting) [9].

In HIV-negative GBMSM, the observed risk has been lower than their HIV-positive peers; although their incidence is reported to be higher than general population and rising in some occidental countries [9,10,12]. Some explanations include chemsex and increased condomless serosorting practices due to HIV pre-exposure prophylaxis (PrEP) [5], overlapping the sexual networks between HIV-positive and negative GBMSM [14]. A systematic review described that, in HIV-negative GBMSM who do not use PrEP, the pooled HCV incidence was 0.12 per 1000 person-years (95% confidence interval [CI] 0.00–0.72) while in PrEP users this pooled incidence was 14.80 per 1000 person-years (9.65–20.95) [7]. Moreover, few studies have specifically looked at how social and structural factors facilitate HCV transmission, what is missing in HCV information and support for GBMSM, or the efficacy of specific HCV interventions in GBMSM [9,15].

In Spain, according to the second National Study of HCV seroprevalence (2017–2018) [16], the prevalence of HCV antibodies among 20–80s is an estimated 0.85% (95% CI: 0.64–1.08%) and the prevalence of active HCV infection is 0.22% (0.12–0.32%). According to the National Centre of Epidemiology [1], by 2020, 819 cases were notified across Spain (incidence rate of 2.36 per 100.000 citizens) but of those only 7.8% (n = 64) were confirmed as active cases. Among Spain's HIV-negative GBMSM, the data remains unclear. In order to provide clinical recommendations for HCV screening key populations, the aim of this study is to estimate the HCV antibodies prevalence and active HCV infection in HIV-negative GBMSM of Barcelona and Madrid, from March 2018 to March 2021, and their characteristics.

Methodology

Study design

This cross-sectional study was carried out using a structured, virtual, and self-administered questionnaire, from March 2018 to March 2021 in the two most populated cities of Spain. The study took place in two STI-specific clinics, references in each city (Drassanes Express in Barcelona,

and Sandoval Clinic in Madrid), and two community programs for rapid HIV testing: the Rapid Test Program of the Epidemiologic Service of Barcelona's Public Health Agency, and Madrid's Pink Peace Program. The STI clinics primarily offer on-demand services, PrEP delivery, and conduct standard testing for all STIs in accordance with Spain's guidelines [17]. In contrast, community programs provide rapid testing for HIV (Determine™ HIV-1/2), syphilis (Determine™ Syphilis TP), and during this study, for HCV (OraQuick® HCV Rapid Antibody Test [Ora-Sure Technologies, Inc]). Additionally, they employ various methods of active recruitment, including creating profiles on popular dating apps targeting GBMSM.

Population and sample selection

All cisgender males voluntarily attending STI clinics were approached in the waiting room by researchers, commenting on the aim of the study and the inclusion criteria. HIV-negative individuals, who reported sex with partners of the same gender, were asked to participate before or after the consultation. If agreed, a researcher provided them with a digital tablet with the online survey to be answered in the waiting room. Attenders to community programs, when identified as GBMSM by the community worker, were asked to complete the online survey using a tablet provided by the same worker while awaiting results. If a reactive HCV test was detected in a community program, the participant was referred to the local specialized STI center for HCV-RNA detection and viral load determination.

Questionnaire and data collection

Researchers developed an anonymous, self-administered questionnaire in the SurveyMonkey platform, to be administered via tablet during or after the consultation. Depending on the participant's responses, it could take a minimum of 20 minutes, with the potential for additional time when answering questions related to sexualized drug consumption. The questionnaire covered various topics, including sociodemographic information, history of HIV and HCV testing, HCV knowledge, sexual behaviors, and both recreational and sexualized drug use history. The data obtained from participants were coded and kept anonymous. Later, the research team linked this anonymized data to the HIV and HCV results. The team also verified previous diagnoses and RNA negativization before categorizing cases as reinfection.

Variables

Prevalence of HCV antibodies (AB) was defined as having a reactive HCV rapid test in the community centers or a positive ELISA in STI centers. A reactive HCV rapid test with presence of HCV-RNA was defined as active HCV infection (AC). Sociodemographic data included age, country of birth, employment status, educational level, economic welfare, and disclosure of sexual orientation. HCV history includes previous HCV diagnosis and treatment, previous hepatitis A and B vaccination, previous tattoos or piercings, and knowledge about hepatitis. Sexual health history included previous STI diagnosis, previous HIV/STI testing, and sexual behavior practices, such as lifetime and last year receptive penetrative sex, unprotected receptive sex, and sex with women; receiving fingering or fisting; sharing douching material, sex toys or lubricant; group sex, or visible bleeding after sex. Also includes consuming or practicing male sex work and venues to find sexual partners. To evaluate sexualized drug use, different drugs, including erectile medication, opioids, and sedatives were listed. For each one it was quantified general and sexualized use. Moreover, the questionnaire evaluated the proportion of sex under influence of drugs in the last year, mixing drugs and alcohol, injecting drugs for sex, and sharing injectable or snorting material, quantifying total times and time of last practices. Previous analysis of this database in relation to drug surveillance have been published [13,18].




Figure 1. Flowchart according to city of testing and type of facility. Results are presented in absolute frequency and prevalence with 95% confidence interval, according to their HIV status. AB, antibody; GBMSM, gay, bisexual, and other men who have sex with men; HCV, hepatitis C virus; STI, sexually transmitted infection.

Analysis

The prevalence for both HCV antibodies and active infection was calculated according to those with a negative HIV test during consultation. Results are presented in a flowchart in percentages and 95% CIs, with percentages regarding city and type of program of testing. Then, a descriptive analysis of those HCV (+) was performed according to presence or absence of HCV-RNA, and the rest of HIV-negative cases. HIV-positive and total sample are presented in Supplementary material 1. Poisson regression models with robust variations were made for both the presence of antibodies and for active infection, compared with being HCV/HIV-negative. Models were presented in crude prevalence ratios, and adjusted by age, country of birth, study level, economic welfare, and sexual orientation disclosure (adjusted prevalence ratio 1 [APR1]). Those significant (<0.05) were explored to create a single adjusted Poisson model for each dependent variable (APR2). Non-significant variables, and crude prevalence ratio/APR for those with presence of HCV antibodies, but RNA negative, are presented in the Supplementary material 2. All the analyses were carried out in STATA 15 and 16.

Ethical considerations

Each participant signed an informed consent accepting to participate voluntarily, after being explained the aim of the study and the confidentiality of the obtained data. To guarantee confidentiality of the data and records, we adhered to the regulations established by the Organic Law on the Protection of Personal Data 15/1999 in Spain and the successive updates. The project was approved by Research Ethics Committee of Parc de Salut Mar, on June 25, 2019, and by the Research Ethics Committee of the Instituto de Salud Carlos III (CEI PI 44_2018_subproyecto1-v2 and CEI PI 44_2018_subproyecto2).

Results

From March 2018 to March 2021, 3548 participants attended any of the services in Barcelona or Madrid, where 97.6% (n = 3463) were

HIV-negative. Of them, 18 participants (0.52%, 95% CI: 0.33-0.82) tested positive for HCV AB, of which nine participants (0.26% 95% CI: 0.14-0.49) were diagnosed later with an active HCV (AC). Of the 2.4% (n = 85) participants who tested positive for HIV, some 3.5% (n = 3) tested also positive for HCV AB, with 2.4% (n = 2) presenting an active HCV (Figure 1).

Most HIV-negative cases with a reactive HCV test (AB/AC) had attended university education, had a subjective comfortable economic welfare, and lived an openly sexual orientation between their peers. Most of the cases had sex exclusively with men and had been tested for HIV in the last 6 months. In total, 77.8% of the cases (AB/AC) have had some STI in their lifetime, mostly syphilis and gonorrhea, and mostly had their last STI during the last year. Two of the nine diagnosed with an AC-HCV have had a previous HCV diagnosis. Between the participants, the best-known statement was the existence of several types of hepatitis named by letters of the alphabet, and the worst known was that healthcare providers recommend that GBMSM gets vaccinated against viral hepatitis A and B. Some 66.7% of AC-HCV had ever shared douching material and some 77.8% had ever participated in group sex. All AC-HCV cases reported use of drugs related to sex (AB: 77.8%). Injectible drug use was described by 83.3% of HCV AB and 66.7% of HCV-AC (Table 1).

In the single Poisson model, those with HCV antibodies were associated to have ever lived with an HCV (+) person (APR: 7.84, [95% CI: 2.50-24.53]), ever using injectable drugs for sex (APR: 6.92, [1.20-39.79]) and referring an STI in the previous year (4.06, [1.09-15.12]). The adjusted models found associations with previous STIs (syphilis and chlamydia), higher amount of condomless encounters with different sexual partners, group sex, and sex work. Furthermore, presenting an active infection was strongly associated with a previous HCV diagnosis (APR: 100.82 [22.16-458.76]), also to sexualized injectable drug use (APR: 17.53 [2.70-113.76]) and to ever have shared douching material (APR: 7.45, [2.12-25.95]). Similar to AB-HCV, associations were found with a higher amount of condomless sexual partners, previous syphilis, and sharing shaving material with HCV partners, but also for sharing sniffing material for sex, and the use of gamma-hydroxybutyrate/gamma-hydroxybutyrolactone (GHB/GBL) (Table 2).

Table 1a
Descriptive of the sample. Only those HIV (-) are presented. Sociodemographic and HCV practices and knowledge.

	HCV AB (+) HIV (-) (a)				HCV (-) HIV (-) (n = 3445)		Total HIV (-) (n = 3463)	
	RNA (+) (n = 9)		RNA (-)(n = 9)		N	%	N	%
	N	%	N	%				
Age in three groups								
Under 30 years old	2	22.2	3	33.3	1348	39.1	1353	39.07
Between 30-39 years	6	66.7	3	33.3	1182	34.3	1191	34.39
40 years or more	1	11.1	3	33.3	915	26.6	919	26.54
Country of birth								
Spain	4	44.4	5	55.6	2164	62.8	2173	62.75
Latin-America	3	33.3	4	44.4	914	26.5	921	26.59
Others	2	22.2	0	0	367	10.7	369	10.66
Study level								
None or primary	1	11.1	0	0	234	6.8	235	6.79
Secondary	1	11.1	1	11.1	1143	33.2	1145	33.06
University or more	7	77.8	8	88.9	2056	59.7	2071	59.80
Missing values	0	0	0	0	12	0.3	12	0.35
Economic welfare last year								
Comfortable	7	77.8	6	66.7	2055	59.7	2068	59.72
Thigh, hard or very hard	2	22.2	3	33.3	1343	39	1348	38.93
Missing values	0	0	0	0	47	1.4	47	1.36
Orientation disclosure with others								
Openly	6	66.7	6	66.7	2093	60.8	2105	60.79
Not openly	3	33.3	3	33.3	1299	37.7	1305	37.68
Missing values	0	0	0	0	53	1.5	53	1.53
Employment status								
Employed	4	44.4	5	55.6	1723	50.0	1732	50.01
Unemployed	1	11.1	0	0	168	4.9	169	4.88
Others	0	0	0	0	421	12.2	421	12.16
Missing values	4	44.4	4	44.4	1133	32.9	1141	32.95
Sex also with women								
Exclusively with men	5	55.6	6	66.7	2154	62.5	2165	62.52
Occasionally	2	22.2	3	33.3	1044	30.3	1049	30.29
Frequently	2	22.2	0	0	247	7.2	249	7.19
Vaccinated against hepatitis A								
Yes	3	33.3	7	77.8	1876	54.5	1886	54.46
No	2	22.2	0	0	484	14	486	14.03
Unknown	4	44.4	2	22.2	1085	31.4	1091	31.50
Vaccinated against hepatitis B								
Yes	4	44.4	8	88.9	1842	53.5	1854	53.54
No	1	11.1	0	0	387	11.2	388	11.20
Unknown	4	44.4	1	11.1	1216	35.3	1221	35.26
Ever being tested for HCV								
Yes	5	55.6	8	88.9	1536	44.6	1549	44.73
No	1	11.1	0	0	836	24.3	837	24.17
Unknown	3	33.3	1	11.1	1073	31.2	1077	31.10
Ever being diagnosed HCV								
No	7	77.8	1	11.1	3408	98.9	3416	98.64
Yes	2	22.2	8	88.9	24	0.7	34	0.98
Missing values	0	0	0	0	13	0.4	13	0.38
Knowing that viruses cause most hepatitis								
knows it	6	66.7	6	66.7	1996	57.9	2008	57.98
US/UK/DU/DB(b)	3	33.3	2	22.2	1425	41.4	1430	41.29
Missing values	0	0	1	11.1	24	0.7	25	0.72
Knowing that there are several types of viral hepatitis, named by the letters of the alphabet								
knows it	7	77.8	9	100	3049	88.5	3065	88.51
US/UK/DU/DB(b)	2	22.2	0	0	360	10.4	362	10.45
Missing values	0	0	0	0	36	1.0	36	1.04
Knowing that there are only vaccines for hepatitis A and hepatitis B, but not for hepatitis C.								
knows it	4	44.4	7	77.8	1700	49.3	1711	49.41
US/UK/DU/DB(b)	5	55.6	2	22.2	1710	49.6	1717	49.58
Missing values	0	0	0	0	35	1.0	35	1.01
Knowing that health care providers recommend that men who have sex with men get vaccinated								
knows it	4	44.4	5	55.6	1843	53.5	1852	53.48
US/UK/DU/DB(b)	5	55.6	4	44.4	1566	45.5	1575	45.48
Missing values	0	0	0	0	36	1.0	36	1.04
Knowing that people who have HIV are more likely to be infected with hepatitis.								
knows it	4	44.4	6	66.7	1399	40.6	1409	40.69
US/UK/DU/DB(b)	5	55.6	3	33.3	2009	58.3	2017	58.24
Missing values	0	0	0	0	37	1.1	37	1.07

(a) HCV: Hepatitis C virus; AB: antibodies. (b) US, UK, DU, DB: Unsure, unknown, don't understand it or don't believe it

Table 1b
Descriptive of the sample. Sexual health and sexual behaviors.

	HCV AB (+) HIV (-) (a)				HCV (-) HIV (-) (n = 3445)		Total HIV (-) (n = 3463)	
	RNA (+) (n = 9)		RNA (-)(n = 9)		N	%	N	%
	N	%	N	%				
Last HIV testing								
In the last 6 months	8	88.9	7	77.8	1691	49.1	1706	49.26
More than 6 months ago	0	0	2	22.2	1532	44.5	1534	44.29
Never tested before	1	11.1	0	0	222	6.5	223	6.44
Lifetime STI (a) (multiple options)								
Syphilis	6	66.7	4	44.4	803	23.3	813	23.48
Gonorrhea	5	55.6	5	55.6	1121	32.5	1131	32.66
Chlamydia	4	44.4	5	55.6	613	17.8	622	17.96
Lymphogranuloma	0	0	0	0	20	0.6	20	0.58
Last diagnosed STI								
More than 1 year ago	2	22.2	1	11.1	941	27.3	944	27.26
During the last year	5	55.6	6	66.7	1010	29.3	1021	29.48
Missing values	2	22.2	2	22.2	1494	43.4	1498	43.26
Lifetime condomless received penetration								
None	0	0	0	0	554	16.1	554	15.99
Less than five people	2	22.2	1	11.1	1790	52.0	1793	51.78
More than five people	7	77.8	8	88.9	1087	31.6	1102	31.82
Missing values	0	0	0	0	14	0.4	14	0.40
Lifetime HIV (+) condomless received penetrations								
None	5	55.6	6	66.7	2507	72.8	2518	72.71
Some	4	44.4	3	33.3	566	16.4	573	16.55
Missing values	0	0	0	0	372	10.8	372	10.74
Last year condomless received penetrations								
None	1	11.1	0	0	819	23.8	820	23.68
Less than five people	5	55.6	7	77.8	1767	51.3	1779	51.37
More than five people	2	22.2	2	22.2	326	9.5	330	9.53
Missing values	1	11.1	0	0	533	15.5	534	15.42
Lifetime unprotected anal fingering								
None	3	33.3	4	44.4	1338	38.8	1345	38.84
Some	6	66.7	5	55.6	2097	60.9	2108	60.87
Missing values	0	0	0	0	10	0.3	10	0.29
Lifetime fisting								
None	7	77.8	8	88.9	3239	94.0	3254	93.96
Some	2	22.2	1	11.1	202	5.9	205	5.92
Missing values	0	0	0	0	4	0.1	4	0.12
Ever having visible bleeding after unprotected anal penetration								
None	5	55.6	5	55.6	2436	70.7	2446	70.63
Some	4	44.4	4	44.4	1008	29.3	1016	29.34
Missing values	0	0	0	0	1	0	1	0.03
Ever sharing unprotected sex toys								
None	8	88.9	9	100	3005	87.2	3022	87.27
Some	1	11.1	0	0	434	12.6	435	12.56
Missing values	0	0	0	0	6	0.2	6	0.17
Ever sharing lubricant from the same pot								
None	3	33.3	3	33.3	1340	38.9	1346	38.87
Some	6	66.7	6	66.7	2088	60.6	2100	60.64
Missing values	0	0	0	0	17	0.5	17	0.49
Ever sharing douching material								
None	3	33.3	7	77.8	2751	79.9	2761	79.73
Some	6	66.7	2	22.2	689	20.0	697	20.13
Missing values	0	0	0	0	5	0.1	5	0.14
Participating in group sex (being penetrated by two or more men in one session)								
None	2	22.2	4	44.4	2267	65.8	2273	65.64
Some	7	77.8	5	55.6	1170	34.0	1182	34.13
Missing values	0	0	0	0	8	0.2	8	0.23
Ever pay a man for sex								
None	7	77.8	8	88.9	2842	82.5	2857	82.50
Some	2	22.2	1	11.1	603	17.5	606	17.49
Ever been paid for sex								
None	4	44.4	6	66.7	2705	78.5	2715	78.40
Some	5	55.6	3	33.3	739	21.5	747	21.57
Missing values	0	0	0	0	1	0	1	0.03
Lifetime sexualized use of drugs (multiple options)								
Poppers	6	66.7	4	44.4	1456	42.3	1466	42.33
Erectile medication	4	44.4	2	22.2	695	20.2	701	20.24
Sedatives or tranquilizers	0	0	1	11.1	58	1.7	59	1.70
Cannabis or synthetic cannabinoids	1	11.1	3	33.3	727	21.1	731	21.11
Powder or crack cocaine	4	44.4	2	22.2	534	15.5	540	15.59
Heroin or other opium derivatives	1	11.1	0	0	11	0.3	12	0.35
Amphetamine	3	33.3	1	11.1	222	6.4	226	6.53

(continued on next page)

Table 1b (continued)

	HCV AB (+) HIV (-) (a)				HCV (-) HIV (-) (n = 3445)		Total HIV (-) (n = 3463)	
	RNA (+) (n = 9)		RNA (-)(n = 9)		N	%	N	%
	N	%	N	%				
Ecstasy or MDMA (b) in its pill or crystal form	1	11.1	2	22.2	430	12.5	433	12.50
Methamphetamine	3	33.3	1	11.1	268	7.8	272	7.85
Mephedrone	3	33.3	0	0	267	7.8	270	7.79
Gamma-hydroxybutyrate/ gamma-hydroxybutirolactone	4	44.4	1	11.1	459	13.3	464	13.39
Ketamine	2	22.2	0	0	245	7.1	247	7.13
LSD (c)	0	0	0	0	58	1.7	58	1.67
Lifetime use of alcohol during sex								
None	2	22.2	4	44.4	1108	32.2	1114	32.17
Less than 10 times	2	22.2	2	22.2	1367	39.7	1371	39.58
More than 10 times	5	55.6	3	33.3	942	27.3	950	27.43
Missing values	0	0	0	0	28	0.8	28	0.81
Injectable drug use, for sex								
Yes	6	66.7	9	100	3352	97.3	3367	97.23
No	3	33.3	0	0	51	1.5	54	1.56
Missing values	0	0	0	0	42	1.2	42	1.21
Sharing sniffing material, for sex								
None	3	33.3	8	88.9	2813	81.7	2824	81.55
Some	5	55.6	1	11.1	589	17.1	595	17.18
Missing values	1	11.1	0	0	43	1.2	44	1.27

(a) STI: sexually transmitted infection.(b) MDMA: 3,4-metilendioxi-metanfetamina (c) LSD: Lysergic acid diethylamide.

Discussion

Our study results estimate that HCV seroprevalence and active infection in HIV-negative GBMSM from Barcelona and Madrid are similar to the prevalence among the general population. However, individuals with a history of HCV were positively associated with a range of sexual behaviors epidemiologically linked to an increased risk of bleeding, particularly condomless anal sex, an elevated number of penetrations in a given sexual encounter, and sexualized drug consumption. Other practices with risk of blood-sharing observed with this population include group sex participation and sharing douching, sniffing, or injection materials.

Our HCV antibody prevalence seem a bit lower than what has been observed in previous reports on HIV-negative GBMSM [7,12], although they correlate very well with previous analysis of this population conducted in community centers in Barcelona [19,20]. Systematic review from Jin et al. [7] described a general HCV seroprevalence in GBMSM of 3.4% (2.5-10.4%), independent of their HIV status, and 1.5% (1.0-2.1%) in HIV-negative GBMSM. Zheng et al. [12]'s review pooled an HCV prevalence of 5.9% (5.1-6.8%) in general GBMSM and 2.8% (1.9-4.0%) in the HIV-negative group. In Spain's GBMSM, While earlier studies reported a general prevalence of 4.2% (2.2-6.7%) [7]; they found no cases of HCV in HIV-negative GBMSM (0% [0-0.9%]); Zheng et al. [12]'s study reported a general GBMSM seroprevalence of 6.3% (3.7-9.4%), with a seroprevalence of 3.0% (0.7-6.6%) in HIV-undiagnosed GBMSM, being correlated with our results. Many factors could explain these differences, like the study's region, the sample selection method, or the inclusion of specific populations, such as people who inject drugs (PWID). In Barcelona, Saludes et al. [19] reported an HCV seroprevalence of 0.75% (0.1-1.6%) in 617 HIV-negative GBMSM recruited voluntarily from a community center, while Coll et al. [20] followed 258 HIV-undiagnosed GBMSM from 2009-2012, recruited as well from community centers, finding an HCV seroprevalence of 2.0% (0.7-4.8%), both similar with our results. Furthermore, Jin et al. [7]'s results describe that HCV seroprevalence was higher in low and lower-middle-income economies, independent of their HIV status, unlike Spain, which is close to HCV eradication [2], and other countries that have adopted DAA strategies [21]. Other studies evaluating HCV seroprevalence in GBMSM in Spain begin by recruiting HIV-positive individuals and assessing the coinfection risk. In our sample, those who received an HIV diagnosis presented an HCV antibody prevalence of 3.53% (1.21-9.87) and a preva-

lence of active infection of 2.35% (0.65-8.18), supporting the correlation between these two infections [7,9,11].

Both antibodies and presenting an active HCV were strongly associated with ever being in close contact with an HCV partner diagnosed, especially if they have previously shared shaving material. Moreover, presenting an active infection was strongly associated with a previous HCV diagnosis, supporting previous evidence of reinfection risk [22]. Ever being paid for sex presented significant associations in both adjusted models but may have interacted with other variables in the final models, like slamming or sharing douching material. It is important, for screening and surveillance implications, the correct identification of key populations, contact tracing when a diagnosis is made, and the linkage for regular testing in an HCV-diagnosed patient. Adu et al. [23] found that in reinfected HCV HIV (+) GBMSM, mental health counseling could reduce the risk of reinfection, so targeted interventions could be beneficial also in those HIV-negative.

PWID, in general, has been targeted as a key population for HCV eradication [2,24], with reported seroprevalence in European PWID ranging from 7-95% and national PWID's seroprevalence estimated at 66.6% [25]. Due to this previous assumption, we expected the high association of seroprevalence observed with ever using heroin or using injectable drugs, for any purpose. PWID who also identifies as GBMSM may constitute a unique group with an increased risk of HCV acquisition. Moreover, high rates of injecting drug use appear to be one of the main drivers of the HCV epidemic in this population. In our sample, the association of using injectable drugs for sex was higher than using them for any purpose. Previous analyses on this sample have been published on this subject [13], describing associations with an increased number of sex partners and meeting them in private parties. Slamming sex is a practice reported to be rising among individuals practicing chemsex [7,13,26], so screening and preventive interventions during sexual health consultation should be mandatory [27]. Previous data published in this sample observed a significant increase compared with previous Spanish reports, where 81.9% of first injectors were in a sexual context, 62.7% started with mephedrone, and 32.2% with methamphetamine [13].

Mephedrone and Crystal Methamphetamine have been recognized as two of the drugs in "4-Chem", along with GHB/GBL and ketamine [18], with an increasing amount of research focused on their sexualized use within GBMSM communities, and their effects [28]. Although a single definition for chemsex does not yet exist [29,30], the

Table 2

Crude and adjusted Poisson regression with robust variance for HCV antibodies prevalence and active infection. APR is adjusted by age, country of origin, study level, economic welfare, and orientation disclosure (APR1), while APR2 is a single model with adjusted and significant variables. Only significant variables are presented. For more information refer to Supplementary material 2.

	HCV antibodies prevalence						Active HCV infection					
	HCV AB (+) HIV(−), (n = 18)						HCV AB (+) RNA (+) HIV(−), (n = 9)					
	CPR	95% CI	APR (1)	95% CI	APR (2)	95% CI	CPR	95% CI	APR (1)	95% CI	APR (2)	95% CI
Age (three groups)												
Under 30 years old	1		1		1		1		1		1	
Between 30-39 years	2.07	0.69-6.16	1.75	0.61-5.05	2.62	0.68-10.14	3.45	0.69-17.08	2.84	0.59-13.60	2.93	0.70-12.18
40 years or more	1.21	0.32-4.48	1.11	0.28-4.34	1.63	0.32-8.22	0.75	0.06-8.31	0.64	0.05-8.63	0.6	0.10-3.61
Country of birth												
Spain	1		1		1		1		1		1	
Latin-America	1.77	0.66-4.73	2.22	0.82-5.98	2.07	0.65-6.59	1.71	0.38-7.61	2.04	0.45-9.13	1.75	0.38-8.13
Others	1.30	0.28-6.00	1.19	0.26-5.45	0.74	0.09-5.84	2.93	0.54-15.94	2.59	0.47-14.06	5.06	0.94-27.16
Study level												
None or primary	1		1				1		1		1	
Mandatory secondary	0.41	0.04-4.54	0.38	0.03-4.52	^a		0.21	0.01-3.29	0.18	0.01-3.29	0.11	0.01-1.96
University or more	1.74	0.23-13.18	1.55	0.19-12.89	^a		0.82	0.10-6.60	0.59	0.06-5.91	0.98	0.14-6.87
Economic welfare last year												
Comfortable	1		1		1		1		1		1	
Thigh. hard/very hard	0.58	0.21-1.62	0.62	0.21-1.82	0.55	0.16-1.81	0.43	0.09-2.06	0.43	0.08-2.23	0.46	0.09-2.21
Employment status												
Employed	1		1				1		1			
Unemployed	1.04	0.13-8.15	1.64	0.14-19.48			2.33	0.26-20.81	4.78	0.27-86.29		
Orientation disclosure												
Openly	1		1		1		1		1		1	
Not openly	0.79	0.30-2.13	0.79	0.27-2.31	0.89	0.27-3.02	0.79	0.20-3.19	0.9	0.22-3.67	1.51	0.30-7.59
Sex also with women												
Exclusively with men	1		1				1		1			
Occasionally	0.94	0.33-2.69	0.95	0.33-2.72			0.82	0.16-4.24	0.86	0.17-4.32		
Frequently	1.59	0.35-7.12	2.38	0.54-10.43			3.49	0.67-17.92	6.37	1.74-23.26		
Last HIV testing												
In the last 6 months	1		1				1		1			
More than 6 months ago	0.15	0.03-0.64	0.15	0.03-0.67			^a		^a			
Never tested before	0.51	0.07-3.89	0.84	0.09-7.79			0.96	0.12-7.66	1.75	0.15-19.86		
Lifetime STI (multiple option)												
Syphilis	4.06	1.61-10.26	4.09	1.51-11.11			6.49	1.63-25.93	6.33	1.52-26.35		
Gonorrhea	2.61	1.03-6.59	2.45	0.89-6.69			2.61	0.70-9.69	2.33	0.62-8.88		
Chlamydia	4.66	1.86-11.71	4.61	1.67-12.70			3.73	1.00-13.91	3.42	0.86-13.61		
Last diagnosed STI												
More than 1 year ago	1		1		1		1		1			
During the last year	3.38	0.94-12.06	3.79	1.06-13.63	4.06	1.09-15.12	2.30	0.44-11.84	2.36	0.44-12.74		
Lifetime received penetrations												
Less than 50 people	1		1				1		1			
More than 50 people	4.22	1.64-10.85	4.32	1.64-12.00			1.34	0.34-5.36	1.21	0.27-5.33		
Lifetime condomless received penetration												
Less than five people	1		1				1		1			
More than five people	8.01	2.32-27.66	8.86	2.52-31.14			5.60	1.17-26.94	5.83	1.18-28.73		
Lifetime HIV (+) condomless received penetrations												
None	1		1				1		1			
Some	2.79	1.08-7.20	2.89	1.09-7.69			3.51	0.94-13.03	3.39	0.70-16.43		
Last year condomless received penetrations												
None	1		1				1		1			
Less than five people	5.44	0.71-41.78	5.58	0.69-44.71			2.27	0.27-19.38	2.32	0.25-21.22		
More than five people	9.58	1.07-85.43	10.19	1.00-103.95			4.79	0.43-52.66	4.51	0.31-66.48		

(continued on next page)

Table 2 (continued)

	HCV antibodies prevalence						Active HCV infection					
	HCV AB (+) HIV(-), (n = 18)						HCV AB (+) RNA (+) HIV(-), (n = 9)					
	CPR	95% CI	APR (1)	95% CI	APR (2)	95% CI	CPR	95% CI	APR (1)	95% CI	APR (2)	95% CI
Sharing douching material												
No	1		1				1		1		1	
Yes	3.17	1.26-8.00	3.38	1.29-8.82			7.92	1.98-31.69	8.45	2.08-34.41	7.45	2.12-25.95
Group sex (penetrated by two or more men in one session)												
No	1		1				1		1			
Yes	3.78	1.42-10.05	3.61	1.21-10.76			6.62	1.38-31.81	6.03	1.01-35.91		
Ever been paid for sex												
No	1		1				1		1			
Yes	2.89	1.14-7.29	3.50	1.42-8.60			4.51	1.21-16.78	5.44	1.41-21.04		
Ever being diagnosed HCV												
No	1		1				1		1		1	
^b Yes	128.68	54.1-306.0	175.57	63.65-476.12			29.41	6.11-141.58	37.29	7.10-195.86	100.82	22.16-458.76
Have lived with an HCV(+) person												
No	1		1		1		1		1			
Yes	6.67	2.40-18.53	6.99	2.42-20.21	7.84	2.50-24.53	4.96	1.04-23.71	5.81	0.99-33.87		
Shared razors or shaving brushes with an HCV(+) person												
No	1		1				1		1			
Yes	27.56	6.89-110.19	28.54	6.48-125.68			27.56	3.66-207.83	33.21	4.24-259.99		
Lifetime sexualized use of drugs (multiple option)												
Poppers	1.71	0.68-4.32	1.59	0.62-4.11			2.73	0.69-10.93	2.47	0.59-10.31		
Erectile medication	1.97	0.74-5.23	1.80	0.59-5.45			3.15	0.85-11.71	3.05	0.75-12.51		
Cannabis or synthetic cannabinoids	1.07	0.35-3.25	1.04	0.35-3.06			0.47	0.06-3.74	0.44	0.06-3.08		
Powder or crack cocaine	2.71	1.02-7.20	2.81	0.88-8.97			4.34	1.17-16.12	4.21	0.76-23.27		
Heroin or other opium derivatives	17.33	2.50-120.11	16.45	1.99-135.97			36.83	4.98-272.27	39.15	4.39-349.15		
Ecstasy or MDMA in its pill or crystal form	1.41	0.41-4.84	1.31	0.34-5.01			0.88	0.11-7.02	0.77	0.08-7.91		
Amphetamine	4.12	1.36-12.42	4.31	1.42-13.13			7.21	1.82-28.66	6.83	1.78-26.12		
Methamphetamine	3.35	1.11-10.10	3.43	1.02-11.51			5.86	1.47-23.30	5.61	1.20-26.15		
Mephedrone	2.31	0.67-7.92	2.22	0.62-7.97			5.77	1.45-22.94	5.33	1.17-24.11		
Gamma-hydroxybutyrate/ gamma-hydroxybutyrolactone	2.46	0.88-6.88	2.36	0.77-7.20			5.12	1.38-19.02	4.68	1.18-18.54		
Ketamine	1.57	0.36-6.78	1.54	0.33-7.19			3.58	0.75-17.17	3.29	0.58-18.64		
Injectable drug use. for sex												
Yes	1		1		1		1		1		1	
No	12.55	3.74-42.10	12.26	3.26-46.13	6.92	1.20-39.79	31.36	7.84-125.41	33.36	7.63-145.74	17.53	2.70-113.76
Sharing sniffing material. for sex												
No	1		1				1		1			
Yes	2.59	0.96-6.98	2.65	0.91-7.69			7.92	1.89-33.05	8.34	1.74-39.90		

AB, antibody; APR, adjusted prevalence ratio; CI, confidence interval; CPR, crude prevalence ratio; HCV, hepatitis C virus; STI, sexually transmitted infection.

^a Excluded due to no cases.

^b Probably related to previous diagnosis.

practices associated with consuming these substances present a pathway for HCV acquisition, such as participating in group sex or the association with GHB/GBL using, besides the other chem drugs. Unlike others with a clear correlation due to the sniffed or injected pathway of administration, GHB/GBL is orally administrated. This could be explained due to the sexual context where the substances are consumed, where they could facilitate the occurrence of known risk of bleeding practices. Furthermore, social determinant variables such as peer pressure, mental health-related variables, or hegemonic masculinity could increase those related risks [28,30].

Rectal douching, or the use of enemas before sex, has been reported as a risk factor for HIV and other STIs, including HCV [31]. Sharing douching material may be a regular practice in those who practice receptive anal sex (bottoming), especially those who attend saunas or private sex parties. It is important to discuss the normative expectations of an anal sexual encounter, balancing the risk and benefits of a regular douching practice, as well as risk reduction strategies, like utilizing their own instruments and attending regular anal checkups in higher-risk populations [31].

Sexual health services are cost-effective and critical points to addressing sexual behaviors with risk of HCV acquisition [32,33]. Personalized risk reduction strategies should be recommended according to their practices, the number of sexual partners, and the preventive strategies of choice, independent of their gender or sexual orientation. Targeting recommendations in sexually active and non-monogamous individuals, with early detection of bleeding risk practices and sexualized substance use, are key elements to an effective response for current needs as well as future outbreaks and epidemics related to sex [34].

Spain's 2017 guidelines for STI management include a yearly HCV screening, with recommendations on 3-6 months of screening in those of "higher risk", not specifying what indeed defines a "riskier" GBMSM [17]. However, although 6.4% of our total sample was tested for the first time for HIV, only 44.7% of the sample referred to being previously tested for HCV. As the 2022 mpox (monkeypox) outbreak demonstrated, there is a need for homogeneous, integrated, and articulated sexual health-related services, with sanitary, surveillance, and community entities developing effective risk communication strategies, clear and informed, but free of stigma. Considering globalized culture and patterns of human movements, it is possible that practices associated with a higher risk of HCV transmission have also increased in countries where HCV testing policies are less expanded, especially in sexual health context.

Limitations

This study has an important limitation of not including PrEP usage as a variable since the beginning of the study, which was difficult due to the particular political environment around the start of the study. PrEP in Spain was included in the sanitary system in November of 2019, and since then, the number of users has been growing, especially in Barcelona and Madrid. PrEP users who engage in condomless sex are identified as a key population for STI prevention [5,7,14], and between this group, the observed risk of acquiring HCV is reported to be higher than their nonusers' peers, for different causes previously discussed [7,14]. Spanish current guidelines in PrEP management indicates HCV screening at the first visit, without recommendations for further control [35], so better recommendations are needed. Nevertheless, PrEP use should not be seen as a causal correlation of acquiring HCV, but as a tool to improve their sexual health. Regular HCV testing in PrEP users, especially in those with practices with risk of bleeding, among counseling interventions, could impact this increased risk.

Other limitations of this study include the selection bias as a result of recruiting individuals from sexual health centers, which may overrepresent higher-risk GBMSM. However, some compensation may be achieved by designing the recruitment from health care centers and community centers in different cities, which may encompass the dif-

ferent profiles of users in the most populated areas of Spain, who attract GBMSM from other parts of Spain and abroad. The COVID-19 pandemic may have affected the access to sexual health services during a good part of our recruitment, as well as restrictions in mobility, which translated into fewer screening checkups, however, most of the sample was recruited before the confinement period. The cross-sectional design does not allow to define causality, so further research is encouraged. The strengths of this study include the power of the sample, the diversity of recruitment sites in highly concentrated GBMSM cities, and the deep research in bleeding risk practices, hepatitis knowledge, and substance use consumption. Our results reinforce the need to develop clear and updated indications on HCV screening, and better interventions in key populations, understanding the specific characteristics of this population in preparation for stronger services.

Conclusion

During 2018-2021, the risk of HCV infection among Barcelona and Madrid's HIV-negative GBMSM was similar to the general population, but higher in those who engage in sexual practices with bleeding risk, such as slamming, chemsex, and sharing rectal douching material. With the increase of PrEP users, HCV diagnosis between HIV-negative GBMSM may rise, due to regular testing but also to the incorporation of new sexual practices. The increased risk for HIV and STIs in GBMSM responds to multiple factors yet to be better understood. Future research is needed to elucidate the contextual, behavioral, and cultural differences of this group allowing to improve the quality of the continuum of care and strengthen the response to potential outbreaks or epidemics related to sex. Sexual health services should identify these practices early during consultation, promoting targeted risk reduction strategies, such as hepatitis A and B vaccination and regular testing. Frequent testing should be recommended in non-monogamous individuals, according to their individual needs and epidemiological context. When a diagnosis is made, contact tracing is highly recommended for cohabitants and sex partners. Further preventive interventions that address mental health and social determinants of health should be promoted, integrating community entities with healthcare and surveillance systems.

Declarations of competing interest

The authors have no competing interests to declare.

Funding

Both a Health Research Grant (Fondo de Investigación en Salud, FIS P117/02077) and an Intramural Strategy Action Grant (P117CIII/00037), From the Carlos III Institute, at the Science and Innovation Ministry of the Spain Government, supported this study.

Ethical approval

Each participant signed an informed consent accepting to participate voluntarily, after being explained about the aim of the study and the confidentiality of the obtained data. To guarantee confidentiality of the data and records, we adhered to the regulations established by the Organic Law on the Protection of Personal Data 15/1999 in Spain and the successive updates. The project was approved by Research Ethics Committee of Parc de Salut Mar, on June 25, 2019 and by the Research Ethics Committee of the Instituto de Salud Carlos III (CEI PI 44_2018_subproyecto1-v2 and CEI PI 44_2018_subproyecto2).

Author contributions

Patricia García de Olalla (PGO), María José Belza (MJB), Juan-Miguel Guerras (JMG), and María Jesús Barberá (MJB) worked on the conceptualization and first methodology design of the proposed work and trial design. Cristina Rius (CR), PGO, and MJB were in charge

of funding acquisition and project administration, including resources. JMG developed the survey, supervised by MJB and PGO. Then, David Palma (DP), Miguel Alarcón (MA), Jorge García (JG), Oscar Ayerdi (OA), and Mar Vera García (MVG) were in charge of the patient recruitment and acquisition of the data in both cities. JMG and DP independently worked in the data curation, organization of the database and performed the statistical analysis. DP performed the formal analysis for this manuscript, literature search, and wrote the first draft of the manuscript, tables, and figures. PGO, CR, and Andrés Román-Urrestarazu (ARU) have supervised the PhD of DP. PGO, MA, JMG, MJB, ARU, Carles Pericas (CP), and CR worked in the validation and interpretation of data for the work, and supervised DP work in data visualization. All the authors provided editing to the manuscript and their final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MJB and CR have contributed equally to the senior authorship.

Role of funding source

Both FIS P117/02077 and PI17CIII/00037 allowed the development of the research project and data dissemination in congress. None of the funders has any inference in the interpretation of results and recommendations obtained from the conclusions.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijregi.2023.07.001.

References

- Centro Nacional de Epidemiología Vigilancia epidemiológica de la hepatitis C en España, 2020. Madrid; 2022. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/archivos.A-Z/HepatitisC/VigilanciaHepatitisC_2020.pdf [accessed 11 December 2022].
- Kåberg M, Weiland O. Hepatitis C elimination – macro-elimination. *Liver Int* 2020;40:61–6. doi:10.1111/liv.14352.
- European Centre for Disease Prevention and control Hepatitis C - Annual epidemiological report for 2021. Stockholm: European Centre for Disease Prevention and Control; 2022.
- World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021.
- Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. *Curr Opin Infect Dis* 2019;32:31–7. doi:10.1097/QCO.0000000000000515.
- Politi J, Guerras JM, Donat M, Belza MJ, Ronda E, Barrio G, et al. Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. *Hepatology* 2022;75:1247–56. doi:10.1002/hep.32237.
- Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2021;6:39–56. doi:10.1016/S2468-1253(20)30303-4.
- de Sanidad Ministerio. Plan Estratégico para el Abordaje de la hepatitis C en el Sistema Nacional de Salud. Servicios Sociales E Igualdad; 2015. https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/plan_estrategico_hepatitis_C.pdf [accessed 11 December 2022].
- Chan DPC, Sun HY, Wong HTH, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: a review. *Int J Infect Dis* 2016;49:47–58. doi:10.1016/j.ijid.2016.05.030.
- Grov C, Westmoreland DA, Carrico AW, Nash D. Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States. *AIDS Care* 2020;32:74–82. doi:10.1080/09540121.2020.1739204.
- Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000–2016: a systematic review and meta-analysis. *Infection* 2017;45:309–21. doi:10.1007/s15010-016-0975-y.
- Zheng Y, Ying M, Zhou Y, Lin Y, Ren J, Wu J. Global burden and changing trend of hepatitis C virus infection in HIV-positive and HIV-negative MSM: A systematic review and meta-analysis. *Front Med (Lausanne)* 2021;8:774793. doi:10.3389/fmed.2021.774793.
- Guerras JM, García de Olalla P, Belza MJ, de la Fuente L, Palma D, Del Romero J, et al. Sexualized drug injection among men who have sex with men in Madrid and Barcelona as the first episode of drug injecting. *Harm Reduct J* 2021;18:86. doi:10.1186/s12954-021-00531-2.
- Hoorneborg E, Coyer L, Boyd A, Achterbergh RC, van der Loeff MF, Bruisten S, et al. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. *J Hepatol* 2020;72:855–64. doi:10.1016/j.jhep.2019.11.022.
- Conway A, Fernández-López L, Reyes-Urueña J, Casabona JCOBATEST Study Group. Hepatitis C screening in community-based voluntary counselling and testing services in Europe: an observational study from the COBATEST network 2014–2018. *J Community Health* 2020;45:606–14. doi:10.1007/s10900-019-00780-0.
- Estirado Gómez A, Justo Gil S, Limia A, Avellón A, Arce Arnáez A, González-Rubio R, et al. Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey. *Eur J Public Health* 2021;31:1117–22. doi:10.1093/eurpub/ckab069.
- de Sanidad Ministerio, Igualdad Servicios Sociales E. Grupo de Expertos del Grupo de Estudio de Sida de la SEIMC (GESIDA), Secretaría del Plan Nacional sobre el Sida (SPNS), Grupo de Estudio de ITS de la SEIMC (GEITS), and rufo Español para la Investigación de las Enfermedades de Transmisión Sexual de la Academia Española de Dermatología Y Venerología y de la Sociedad Española De Infectología Pediátrica (SEIP). Documento de Consenso sobre Diagnóstico y Tratamiento de las Infecciones de Transmisión Sexual en Adultos. Niños y Adolescentes Marzo; 2017. <https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/docConsensoDiagnosticoTtoITSAdultos.pdf> 2017 [accessed 11 December 2022].
- Guerras JM, Hoyos J, García de Olalla P, de la Fuente L, Herrero L, Palma D, et al. Comparison of polydrug use prevalences and typologies between men who have sex with men and general population men, in Madrid and Barcelona. *Int J Environ Res Public Health* 2021;18:11609. doi:10.3390/ijerph182111609.
- Saludes V, Folch C, Morales-Carmona A, Ferrer L, Fernández-López L, Muñoz R, et al. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain. *J Viral Hepat* 2018;25:236–44. doi:10.1111/jvh.12809.
- Coll J, Videla S, Leon A, Ornelas A, García F, Fernández E, et al. Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. *Clin Microbiol Infect* 2018;24:540–5. doi:10.1016/j.cmi.2017.08.012.
- Harney BL, Sacks-Davis R, Van Santen DK, Traeger M, Wilkinson AL, Asselin J, et al. The incidence of hepatitis C among gay, bisexual, and other men who have sex with men in Australia, 2009–2019. *Clin Infect Dis* 2022;74:1804–11. doi:10.1093/cid/ciab720.
- Midgard H, Weir A, Palmateer N, Re VL III, Pineda JA, Macías J, et al. HCV epidemiology in high-risk groups and the risk of reinfection. *J Hepatol* 2016;65:S33–45. doi:10.1016/j.jhep.2016.07.012.
- Adu PA, Rossi C, Binka M, Wong S, Wilton J, Wong J, et al. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. *Liver Int* 2021;41:482–93. doi:10.1111/liv.14762.
- Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* 2017;5:e1192–207. doi:10.1016/S2214-109X(17)30375-3.
- European Centre for Disease Prevention and Control Hepatitis B and C epidemiology in selected population groups in the EU/EEA. Stockholm: European Centre for Disease Prevention and Control; 2018.
- Scheibein F, Wells J, Henriques S, Van Hout MC. Slam Sex' - sexualized injecting drug use ('SIDU') amongst men who have sex with men (MSM)—A scoping review. *J Homosex* 2021;68:2344–58. doi:10.1080/00918369.2020.1804258.
- Martínez-Rebollar M, De La, Mora L, Campistol M, Cabrera B, Bagué A, De Lazari E, et al. Impact of sexualized substance use and other risk practices on HCV microelimination in gbMSM living with HIV: urgent need for targeted strategies. Results of a retrospective cohort study. *Infect Dis Ther* 2021;10:1253–66. doi:10.1007/s40121-021-00448-0.
- Íncera-Fernández D, Gámez-Guadix M, Moreno-Guillén S. Mental health symptoms associated with sexualized drug use (chemsex) among men who have sex with men: a systematic review. *Int J Environ Res Public Health* 2021;18:13299. doi:10.3390/ijerph182413299.
- Santoro P, Rodríguez R, Morales P, Morano A, Morán M. One 'chemsex' or many? Types of chemsex sessions among gay and other men who have sex with men in Madrid, Spain: findings from a qualitative study. *Int J Drug Policy* 2020;82:102790. doi:10.1016/j.drugpo.2020.102790.
- Strong C, Huang P, Li CW, Ku SW-W, Wu HJ, Bourne A. HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men. *Lancet HIV* 2022;9:e717–25. doi:10.1016/S2352-3018(22)00124-2.
- Li P, Yuan T, Fitzpatrick T, Smith K, Zhao J, Wu G, et al. Association between rectal douching and HIV and other sexually transmitted infections among men who have sex with men: a systematic review and meta-analysis. *Sex Transm Infect* 2019;95:428–36. doi:10.1136/sextrans-2019-053964.
- Macgregor L, Ward Z, Martin NK, Nicholls J, Desai M, Hickson F, et al. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. *J Viral Hepat* 2021;28:897–908. doi:10.1111/jvh.13503.
- Prinsenberg T, Illidge J, Zantkuijl P, Bedert M, Prins M, van der Valk M, et al. Usability, acceptability, and self-reported impact of an innovative hepatitis C reduction intervention for men have sex with men: a mixed methods study. *PLoS One* 2022;17:e0263654. doi:10.1371/journal.pone.0263654.
- Lee VC, Sullivan PS, Baral SD. Global travel and HIV/STI epidemics among MSM: what does the future hold? *Sex Health* 2017;14:51–8. doi:10.1071/SH16099.
- Grupo de Trabajo de PrEP. División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Ministerio de Sanidad. Manual de implementación de un Programa de Profilaxis Preexposición al VIH en España. Actualización diciembre de 2021. Madrid: Ministerio de Sanidad; 2021.